A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy

The objective of this study was to compare subjective health status and its correlates in progressive supranuclear palsy (PSP) and multiple system atrophy (MSA). One hundred eighty‐eight patients with PSP and 286 patients with MSA completed EQ‐5D and Hospital Depression and Anxiety Scale. The impact on mobility, usual activities, and self‐care was similarly high in both groups after similar duration. Fifty‐six percent of PSP and 43% of MSA had probable depression, and 37% of both groups had probable anxiety. Patients with PSP had significantly higher depression scores, but groups did not differ in anxiety scores. Patients with MSA had significantly greater pain/discomfort than patients with PSP. The most important association with subjective health status was with depressive symptoms, which accounted for 38% and 29% of EQ‐5D variance in patients with PSP and MSA, followed by disease severity and anxiety scores. We conclude that depressive symptoms were common in both disorders, but more severe in PSP. Anxiety symptoms affected 37% of patients in both groups and contributed to impaired subjective health status. Pain was more problematic in MSA than PSP. © 2010 Movement Disorder Society

[1]  A. Bonnet,et al.  A stable proportion of Lewy body bearing neurons in the substantia nigra suggests a model in which the Lewy body causes neuronal death , 2010, Neurobiology of Aging.

[2]  Brian Spencer,et al.  Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein , 2009, Proceedings of the National Academy of Sciences.

[3]  A. Aguzzi Cell biology: Beyond the prion principle , 2009, Nature.

[4]  B. Oken THE PLACEBO TREATMENTS IN NEUROSCIENCES: NEW INSIGHTS FROM CLINICAL AND NEUROIMAGING STUDIES , 2009, Neurology.

[5]  Martin Beibel,et al.  Transmission and spreading of tauopathy in transgenic mouse brain , 2009, Nature Cell Biology.

[6]  M. Diamond,et al.  Propagation of Tau Misfolding from the Outside to the Inside of a Cell* , 2009, Journal of Biological Chemistry.

[7]  R. Kopito,et al.  Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates , 2009, Nature Cell Biology.

[8]  R. Hauser,et al.  Transplanted dopaminergic neurons develop PD pathologic changes: A second case report , 2008, Movement disorders : official journal of the Movement Disorder Society.

[9]  O. Lindvall,et al.  Research in motion: the enigma of Parkinson's disease pathology spread , 2008, Nature Reviews Neuroscience.

[10]  A. Berardelli,et al.  Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study. , 2008, Archives of neurology.

[11]  W. Oertel,et al.  Pain sensitivity and descending inhibition of pain in Parkinson’s disease , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[12]  B. Borroni,et al.  Cognitive and behavioral assessment in the early stages of neurodegenerative extrapyramidal syndromes. , 2008, Archives of gerontology and geriatrics (Print).

[13]  R. Hauser,et al.  Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease , 2008, Nature Medicine.

[14]  Elisabet Englund,et al.  Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation , 2008, Nature Medicine.

[15]  E. Quagliato,et al.  Pain in Parkinson's disease: analysis of 50 cases in a clinic of movement disorders. , 2008, Arquivos de neuro-psiquiatria.

[16]  K. Double,et al.  The comparative biology of neuromelanin and lipofuscin in the human brain , 2008, Cellular and Molecular Life Sciences.

[17]  N. Quinn,et al.  Survival in multiple system atrophy , 2008, Movement disorders : official journal of the Movement Disorder Society.

[18]  C. Mathias,et al.  Measuring health‐related quality of life in MSA: The MSA‐QoL , 2007, Movement disorders : official journal of the Movement Disorder Society.

[19]  B. Cormand,et al.  A homozygous tyrosine hydroxylase gene promoter mutation in a patient with dopa-responsive encephalopathy: clinical, biochemical and genetic analysis. , 2007, Molecular genetics and metabolism.

[20]  V. Leuzzi,et al.  Tyrosine Hydroxylase Deficiency Presenting with a Biphasic Clinical Course , 2007, Neuropediatrics.

[21]  L. Golbe,et al.  A clinical rating scale for progressive supranuclear palsy. , 2007, Brain : a journal of neurology.

[22]  J. Kordower,et al.  Age-associated increases of α-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? , 2007, Neurobiology of Disease.

[23]  J. Jankovic,et al.  A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease , 2007, Neurology.

[24]  Y. Agid,et al.  Dihydropteridine reductase deficiency: Levodopa’s long-term effectiveness without dyskinesia , 2006, Neurology.

[25]  M. T. Pellecchia,et al.  Health‐related quality of life in multiple system atrophy , 2006, Movement disorders : official journal of the Movement Disorder Society.

[26]  C. Tanner,et al.  Optimizing the ongoing search for new treatments for Parkinson disease , 2006, Neurology.

[27]  M. T. Pellecchia,et al.  Progression of multiple system atrophy (MSA): A prospective natural history study by the European MSA Study Group (EMSA SG) , 2006, Movement disorders : official journal of the Movement Disorder Society.

[28]  D. Mash,et al.  Natural History of Progressive Supranuclear Palsy: A Clinicopathologic Study from a Population of Brain Donors , 2005, European Neurology.

[29]  A. Schrag,et al.  Depressive symptoms and life satisfaction in patients with multiple system atrophy , 2005, Movement disorders : official journal of the Movement Disorder Society.

[30]  A. Dagher,et al.  Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. , 2005, Brain : a journal of neurology.

[31]  K. Rostásy,et al.  Levodopa‐responsive infantile parkinsonism due to a novel mutation in the tyrosine hydroxylase gene and exacerbation by viral infections , 2005, Movement disorders : official journal of the Movement Disorder Society.

[32]  A. Ormazabal,et al.  HPLC with electrochemical and fluorescence detection procedures for the diagnosis of inborn errors of biogenic amines and pterins , 2005, Journal of Neuroscience Methods.

[33]  R. Wevers,et al.  Long-term course of l-dopa-responsive dystonia caused by tyrosine hydroxylase deficiency , 2004, Neurology.

[34]  D. Perl,et al.  Lewy-body formation is an aggresome-related process: a hypothesis , 2004, The Lancet Neurology.

[35]  S. Kish,et al.  Dopa‐responsive dystonia due to mild tyrosine hydroxylase deficiency , 2004, Annals of neurology.

[36]  M. Jahanshahi,et al.  Health‐related quality of life in patients with progressive supranuclear palsy , 2003, Movement disorders : official journal of the Movement Disorder Society.

[37]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[38]  S. Gabriel,et al.  The Structure of Haplotype Blocks in the Human Genome , 2002, Science.

[39]  V. Fung,et al.  Tyrosine hydroxylase deficiency: Clinical manifestations of catecholamine insufficiency in infancy , 2002, Movement disorders : official journal of the Movement Disorder Society.

[40]  P. Brundin,et al.  Cell Survival and Clinical Outcome Following Intrastriatal Transplantation in Parkinson Disease , 2001, Journal of neuropathology and experimental neurology.

[41]  G M McKhann,et al.  Cell therapy for Parkinson's disease. , 2001, The New England journal of medicine.

[42]  I Litvan,et al.  Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders. , 2001, Archives of neurology.

[43]  S. Kish,et al.  Dopa-responsive dystonia simulating spastic paraplegia due to tyrosine hydroxylase (TH) gene mutations , 2001, Neurology.

[44]  C. Stoll,et al.  Tyrosine hydroxylase deficiency unresponsive to L-dopa treatment with unusual clinical and biochemical presentation , 2000, Journal of Inherited Metabolic Disease.

[45]  A Schrag,et al.  How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population , 2000, Movement disorders : official journal of the Movement Disorder Society.

[46]  R. Palmiter,et al.  Dopamine-Deficient Mice Are Hypersensitive to Dopamine Receptor Agonists , 2000, The Journal of Neuroscience.

[47]  R. Wevers,et al.  Biochemical and molecular genetic characteristics of the severe form of tyrosine hydroxylase deficiency. , 1999, Clinical chemistry.

[48]  Ornella Rimoldi,et al.  Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient , 1999, Nature Neuroscience.

[49]  C. J. Mathias,et al.  Symptoms associated with orthostatic hypotension in pure autonomic failure and multiple system atrophy , 1999, Journal of Neurology.

[50]  C. Marsden,et al.  Sequential bilateral transplantation in Parkinson's disease: effects of the second graft. , 1999, Brain : a journal of neurology.

[51]  F. Girotti,et al.  Affective symptoms in multiple system atrophy and Parkinson’s disease: response to levodopa therapy , 1999, Journal of neurology, neurosurgery, and psychiatry.

[52]  R. Khurana,et al.  Occurrence of depressive symptoms in Shy-Drager syndrome , 1999, Clinical Autonomic Research.

[53]  F. Gabreëls,et al.  Biochemical hallmarks of tyrosine hydroxylase deficiency. , 1998, Clinical chemistry.

[54]  R. Wevers,et al.  A common point mutation in the tyrosine hydroxylase gene in autosomal recessive L-DOPA-responsive dystonia in the Dutch population , 1998, Human Genetics.

[55]  R. Hauser,et al.  Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease , 1998, Movement disorders : official journal of the Movement Disorder Society.

[56]  J. Hodges,et al.  Neuropsychological performance, disease severity, and depression in progressive supranuclear palsy , 1996, Journal of Neurology.

[57]  R. Surtees,et al.  Recessively inherited L-DOPA-responsive parkinsonism in infancy caused by a point mutation (L205P) in the tyrosine hydroxylase gene. , 1996, Human molecular genetics.

[58]  N. Quinn,et al.  Pain in multiple system atrophy , 1996, Journal of Neurology.

[59]  L. Golbe,et al.  Psychiatric symptoms in progressive supranuclear palsy. , 1995, Psychosomatics.

[60]  J. Mallet,et al.  Recessively inherited L-DOPA-responsive dystonia caused by a point mutation (Q381K) in the tyrosine hydroxylase gene. , 1995, Human molecular genetics.

[61]  P R Sanberg,et al.  Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. , 1995, The New England journal of medicine.

[62]  R. Surtees,et al.  Aromatic L‐amino acid decarboxylase deficiency , 1992, Neurology.

[63]  C D Marsden,et al.  Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. , 1990, Science.

[64]  S. Udenfriend,et al.  TYROSINE HYDROXYLASE. THE INITIAL STEP IN NOREPINEPHRINE BIOSYNTHESIS. , 1964, The Journal of biological chemistry.

[65]  B. Dworniczak,et al.  A point mutation in the tyrosine hydroxylase gene associated with Segawa's syndrome , 2004, Human Genetics.

[66]  N. Nishiyama,et al.  Autosomal dominant guanosine triphosphate cyclohydrolase I deficiency (Segawa disease) , 2003, Annals of neurology.

[67]  M. Naumann,et al.  Tyrosine hydroxylase deficiency causes progressive encephalopathy and dopa‐nonresponsive dystonia , 2003, Annals of neurology.

[68]  A. Dahlström,et al.  Differential localization of alpha-, beta- and gamma-synucleins in the rat CNS. , 2002, Neuroscience.

[69]  A. Williams EuroQol : a new facility for the measurement of health-related quality of life , 1990 .

[70]  W. Raub From the National Institutes of Health. , 1990, JAMA.

[71]  A. Kasuya EuroQol--a new facility for the measurement of health-related quality of life. , 1990, Health policy.

[72]  DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group. , 1989, Archives of neurology.

[73]  Anthony E. Lang,et al.  Effect of deprenyl on the progression of disability in early Parkinson's disease. , 1989, The New England journal of medicine.

[74]  G. Huston The Hospital Anxiety and Depression Scale. , 1987, The Journal of rheumatology.